doctor prescribed semaglutide thibodaux Medical Weight Loss Treatments A new randomized, placebo-controlled trial

M.LopezJimenezN

Gastrointestinal Side Effects are the predominant category of adverse reactions: Nausea affects approximately 12-24% of diabetes patients and up to 30% of weight management patients, typically most severe during the first few weeks of treatment or following dose increases Diarrhea occurs in 13-17% of diabetes patients and up to 24% of weight management patients Vomiting is reported by 6-10% of diabetes patients and up to 12% of weight management patients, particularly at higher doses Constipation affects 6-11% of diabetes patients and up to 17% of weight management patients Dyspepsia and abdominal pain occur in 6-9% of patients Decreased appetite is common and contributes to the medication's weight loss effects Gastroesophageal reflux disease (GERD) occurs in some patients, particularly at higher doses These gastrointestinal symptoms typically diminish over time as the body adapts to the medication

These estimates reflect a clinical trial setting in which dose and administration are supervised, so therefore may not provide an accurate estimate of absorption variability and may differ from a real-world T2D setting

D 66 , 125132 (2010) McCoy, A

Okay, this is Smithran or Sumithran and their colleagues out of the University of Melbourne